UpCard

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Torasemide anidruż

Available from:

Vétoquinol SA

ATC code:

QC03CA04

INN (International Name):

Torasemide

Therapeutic group:

Klieb

Therapeutic area:

Għas-sulfonamidi, sempliċi, Ta'limitu dijuretiċi

Therapeutic indications:

Għat-trattament ta 'sinjali kliniċi, inkluż edema u effużjoni, relatati ma' insuffiċjenza tal-qalb konġestiva fil-klieb.

Product summary:

Revision: 2

Authorization status:

Awtorizzat

Authorization date:

2015-07-31

Patient Information leaflet

                                15
B. FULJETT TA’ TAGĦRIF
16
FULJETT TA’ TAGĦRIF:
UPCARD 0.75 MG PILLOLI GĦAL KLIEB
UPCARD 3 MG PILLOLI GĦAL KLIEB
UPCARD 7.5 MG PILLOLI GĦAL KLIEB
UPCARD 18 MG PILLOLI GĦAL KLIEB
1.
L-ISEM U L-INDIRIZZ TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦAT-
TQEGĦID FIS-SUQ U TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦALL-
MANIFATTURA RESPONSABBLI GĦALL-ĦRUĠ TAL-LOTT, JEKK DIFFERENTI
Detentur tal-Awtorizzazzjoni għat-Tqegħid fis-Suq responsabbli
għall-ħrug tal-lott:
Vetoquinol SA
Magny-Vernois
70200 Lure
FRANZA
2.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
UpCard 0.75 mg pilloli għal klieb
UpCard 3 mg pilloli għal klieb
UpCard 7.5 mg pilloli għal klieb
UpCard 18 mg pilloli għal klieb
3.
DIKJARAZZJONI TAS-SUSTANZA ATTIVA U SUSTANZI OĦRA
Kull pillola fiha:
UpCard 0.75 mg pilloli għal klieb
0.75 mg of torasemide
UpCard 3 mg pilloli għal klieb
3 mg of torasemide
UpCard 7.5 mg pilloli għal klieb
7.5 mg of torasemide
UpCard 18 mg pilloli għal klieb
18 mg of torasemide
Il-pilloli ta’ UpCard 0.75 mg huma pilloli oblongi ta’ lewn
bajdani għal ofwajt b’ferq 1 fuq kull naħa.
Il-pilloli jistgħu jinqassmu f’żewġ nofsijiet ugwali.
Il-pilloli UpCard ta’ 3 mg, 7.5 mg u 18 mg huma pilloli oblongi
ta’ lewn bajdani u ofwajt bi 3 ifrieq
fuq kull naħa. Il-pilloli jistgħu jinqassmu fi kwartijiet ugwali.
4.
INDIKAZZJONI(JIET)
Għal trattament ta’ sinjali kliniċi, li jinkludu edema, u
effużjoni, marbuta ma’ insuffiċjenza konġestiva
tal-qalb.
5.
KONTRAINDIKAZZJONIJIET
Tużax f’każijiet ta’ ipersensittività għall-ingredjent attiv
jew wiehed mill-eċċipjenti.
Tużax f’każijiet ta’ falliment tal-kliewi.
Tużax f’każijiet ta’ deidrazzjoni severa, ipovolemija jew
pressjoni baxxa.
Tużax fl-istess waqt ma’ dijuretiċi loop oħrajn.
17
6.
EFFETTI MHUX MIXTIEQA
Żieda fil-parametri tal-kliewi fid-demm u insuffiċjenza tal-kliewi
huma osservati b’mod komuni ħafna
waqt it-trattament.
Bħala riżultat tal-azzjoni dijuretika ta’ torasemide,
emokonċentrazzjoni u, b’mod komuni ħafna ġew
osserv
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
KARRATERISTIĊI TAL-PRODOTT FIL-QOSOR
2
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
UpCard 0.75 mg pilloli għal klieb
UpCard 3 mg pilloli għal klieb
UpCard 7.5 mg pilloli għal klieb
UpCard 18 mg pilloli għal klieb
2.
KOMPOŻIZZJONI KWALITATTIVA U KWANTITATTIVA
Kull pillola fiha:
SUSTANZA ATTIVA:
UpCard 0.75 mg
0.75 mg ta’ torasemide
UpCard 3 mg
3 mg ta’ torasemide
UpCard 7.5 mg
7.5 mg ta’ torasemide
UpCard 18 mg
18 mg ta’ torasemide
Għal lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1
3.
GĦAMLA FARMAĊEWTIKA
Pilloli.
UpCard pilloli ta’ 0.75 mg: pilloli oblongi ta’ lewn bajdani għal
ofwajt b’ferq 1 fuq kull naħa. Il-pilloli
jistgħu jinqassmu f’żewġ nofsijiet ugwali.
UpCard pilloli ta’ 3 mg, 7.5 mg u 18 mg: pilloli oblongi ta’ lewn
bajdani għal ofwajt bi 3 ifrieq fuq
kull naħa. Il-pilloli jistgħu jinqassmu fi kwartijiet ugwali.
4.
TAGĦRIF KLINIKU
4.1
SPEĊI LI FUQHOM SER JINTUŻA L-PRODOTT
Klieb.
4.2
INDIKAZZJONIJIET GĦAL UŻU TAL-PRODOTT LI JISPEĊIFIKAW L-ISPEĊI LI
FUQHOM SE JINTUŻA L-PRODOTT
Għal trattament ta’ sinjali kliniċi, li jinkludu edema, u
effużjoni, marbuta ma’ insuffiċjenza konġestiva
tal-qalb.
4.3
KONTRAINDIKAZZJONIJIET
Tużax f’każijiet ta’ ipersensittività għall-ingredjent attiv
jew wiehed mill-eċċipjenti.
Tużax f’każijiet ta’ falliment tal-kliewi.
Tużax f’każijiet ta’ deidrazzjoni severa, ipovolemija jew
pressjoni baxxa.
Tużax fl-istess waqt ma’ dijuretiċi loop oħrajn.
4.4
TWISSIJIET SPEĊJALI GĦAL KULL SPEĊI LI GĦALIHA HU INDIKAT
IL-PRODOTT
Xejn.
3
4.5
PREKAWZJONIJIET SPEĊJALI GĦALL-UŻU
Prekawzjonijiet speċjali għall-użu fl-annimali
Fi klieb li jippreżentaw kriżi akuta b’edema pulmonari, effużjoni
plewrali u/jew axite li teħtieġ
trattament t’emerġenza, l-użu ta’ mediċini injettabbli għandu
jiġi kkonsidrat qabel kull ħaġa oħra qabel
tinbeda terapija dijuretika orali.
Il-funzjoni renali, l-istat ta’ idrazzjoni u l-istat ta’
elettroliti fis-serum għandhom jiġu monitorati:
- fil-bi
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 14-07-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 14-07-2020
Public Assessment Report Public Assessment Report Bulgarian 06-08-2015
Patient Information leaflet Patient Information leaflet Spanish 14-07-2020
Public Assessment Report Public Assessment Report Spanish 06-08-2015
Patient Information leaflet Patient Information leaflet Czech 14-07-2020
Public Assessment Report Public Assessment Report Czech 06-08-2015
Patient Information leaflet Patient Information leaflet Danish 14-07-2020
Public Assessment Report Public Assessment Report Danish 06-08-2015
Patient Information leaflet Patient Information leaflet German 14-07-2020
Public Assessment Report Public Assessment Report German 06-08-2015
Patient Information leaflet Patient Information leaflet Estonian 14-07-2020
Public Assessment Report Public Assessment Report Estonian 06-08-2015
Patient Information leaflet Patient Information leaflet Greek 14-07-2020
Public Assessment Report Public Assessment Report Greek 06-08-2015
Patient Information leaflet Patient Information leaflet English 14-07-2020
Public Assessment Report Public Assessment Report English 06-08-2015
Patient Information leaflet Patient Information leaflet French 14-07-2020
Public Assessment Report Public Assessment Report French 06-08-2015
Patient Information leaflet Patient Information leaflet Italian 14-07-2020
Public Assessment Report Public Assessment Report Italian 06-08-2015
Patient Information leaflet Patient Information leaflet Latvian 14-07-2020
Public Assessment Report Public Assessment Report Latvian 06-08-2015
Patient Information leaflet Patient Information leaflet Lithuanian 14-07-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 14-07-2020
Public Assessment Report Public Assessment Report Lithuanian 06-08-2015
Patient Information leaflet Patient Information leaflet Hungarian 14-07-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 14-07-2020
Public Assessment Report Public Assessment Report Hungarian 06-08-2015
Patient Information leaflet Patient Information leaflet Dutch 14-07-2020
Public Assessment Report Public Assessment Report Dutch 06-08-2015
Patient Information leaflet Patient Information leaflet Polish 14-07-2020
Public Assessment Report Public Assessment Report Polish 06-08-2015
Patient Information leaflet Patient Information leaflet Portuguese 14-07-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 14-07-2020
Public Assessment Report Public Assessment Report Portuguese 06-08-2015
Patient Information leaflet Patient Information leaflet Romanian 14-07-2020
Public Assessment Report Public Assessment Report Romanian 06-08-2015
Patient Information leaflet Patient Information leaflet Slovak 14-07-2020
Public Assessment Report Public Assessment Report Slovak 06-08-2015
Patient Information leaflet Patient Information leaflet Slovenian 14-07-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 14-07-2020
Public Assessment Report Public Assessment Report Slovenian 06-08-2015
Patient Information leaflet Patient Information leaflet Finnish 14-07-2020
Public Assessment Report Public Assessment Report Finnish 06-08-2015
Patient Information leaflet Patient Information leaflet Swedish 14-07-2020
Public Assessment Report Public Assessment Report Swedish 06-08-2015
Patient Information leaflet Patient Information leaflet Norwegian 14-07-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 14-07-2020
Patient Information leaflet Patient Information leaflet Icelandic 14-07-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 14-07-2020
Patient Information leaflet Patient Information leaflet Croatian 14-07-2020
Public Assessment Report Public Assessment Report Croatian 06-08-2015

Search alerts related to this product

View documents history